ABCC2 and primary biliary cholangitis: In the clinical study, UDCA treatment (900 mg/day for 3 weeks) increases the expression of MRP2 on the bile canalicular membrane in the patients with early-stage primary biliary cholangitis and pregnancy-induced cholestasis [2,37].